by
Tue, Nov 22 2011 12:18:48

Troubles in Biotech VC--A Tweetchat with Daphne Zohar

Xconomy moderated tweetchat with Daphne Zohar from PureTech Ventures

  1. ldtimmerman
    Luke Timmerman@ldtimmerman
    Welcome to the @xconomy #bioVC Twitterchat w/ @daphnezohar of PureTech Ventures. Daphne, can you start w/ a little on what PureTech does?
    Tue, Nov 22 2011 09:00:35
  2. daphnezohar
    Daphne Zohar@daphnezohar
    @ldtimmerman PureTech is institutional founder. We form companies,manage & seed them. Recent HBS case good overview undefined #biovc
    Tue, Nov 22 2011 09:03:59
  3. ldtimmerman
    Luke Timmerman@ldtimmerman
    Which pharma cos support PureTech these days? @xconomy #bioVC
    Tue, Nov 22 2011 09:05:05
  4. LifeSciVC
    Bruce Booth@LifeSciVC
    @Xconomy @daphnezohar #biovc What's the biggest win from PureTech's venture creation efforts and what made it special?
    Tue, Nov 22 2011 09:05:31
  5. daphnezohar
    Daphne Zohar@daphnezohar
    @ldtimmerman @lifescivc 1 example is Enlight which is supported by Merck, JnJ, Lilly, Pfizer, Novo, Abbott + a new pharma TBA soon #biovc
    Tue, Nov 22 2011 09:08:11
  6. steen1969
    Andrew Steen@steen1969
    @lifescivc Good question! Interested in the flip side, too. What failed, why & what learned? @daphnezohar #bioVC
    Tue, Nov 22 2011 09:09:26
  7. ldtimmerman
    Luke Timmerman@ldtimmerman
    With a few VC firms getting out of life sciences, others merging, what effect is this having on innovation? @xconomy #bioVC
    Tue, Nov 22 2011 09:09:26
  8. CenturyofLife
    Ricardo Pedraza@CenturyofLife
    In a Risk Off market, how is seed stage risk going to be adequately funded? #biovc
    Tue, Nov 22 2011 09:09:37
  9. daphnezohar
    Daphne Zohar@daphnezohar
    Here's the right link to the HBS case on PureTech http://hbr.org/product/puretech-ventures-in-2011/an/712419-PDF-ENG?Ntt=puretech #biovc
    Tue, Nov 22 2011 09:09:41
  10. scientre
    Laura Strong@scientre
    @daphnezohar Is PureTech financing same as traditional VC model? #biovc
    Tue, Nov 22 2011 09:10:42
  11. AkikoaCom
    Jens Eckstein@AkikoaCom
    It's unfortunately not only a few getting out of LS, it's a herd! Very concerned about breakthrough innovation in LS! #biovc
    Tue, Nov 22 2011 09:11:39
  12. AkikoaCom
    Jens Eckstein@AkikoaCom
    In a recent exercise tried to count bona fide active early-stage investors globally - barely fills both hands ... #biovc
    Tue, Nov 22 2011 09:13:48
  13. daphnezohar
    Daphne Zohar@daphnezohar
    @ldtimmerman biotech ecosystem is in disarray.Few innovative companies getting launched. Really exciting academic science tho #biovc
    Tue, Nov 22 2011 09:14:26
  14. daphnezohar
    Daphne Zohar@daphnezohar
    RT @AkikoaCom: In a recent exercise tried to count bona fide active early-stage investors globally - barely fills both hands ... #biovc
    Tue, Nov 22 2011 09:14:38
  15. lifesciNYC
    lifesciNYC@lifesciNYC
    #biovc @daphnezohar If there were stronger scientist-entre's out there, wld that help attract more early stage VC to LS?Can they be trained?
    Tue, Nov 22 2011 09:15:07
  16. daphnezohar
    Daphne Zohar@daphnezohar
    @gautamkollu Positives:pharma hungry for innovation. M&A deals for non-approved drugs had Avg value of $480M w/ Avg upfront of $219M #biovc
    Tue, Nov 22 2011 09:15:53
  17. ldtimmerman
    Luke Timmerman@ldtimmerman
    Scary RT @AkikoaCom: In a recent exercise tried to count bona fide active early-stage investors globally--barely fills both hands #biovc
    Tue, Nov 22 2011 09:16:25
  18. _rjw
    Rob Winder@_rjw
    @daphnezohar @ldtimmerman Why are so few being launched? Is it the lack of exit options for investors? #biovc
    Tue, Nov 22 2011 09:16:30
  19. biologypartners
    David Maizenberg@biologypartners
    RT @daphnezohar: @gautamkollu Positives:pharma hungry for innovation. M&A deals for non-approved drugs had Avg value of $480M w/ Avg upfront of $219M #biovc
    Tue, Nov 22 2011 09:16:38
  20. AkikoaCom
    Jens Eckstein@AkikoaCom
    ideas and science seems ok. overall complexity and cost of drug discovery in our time is the problems. no more low hanging fruit .. #biovc
    Tue, Nov 22 2011 09:16:54
  21. ldtimmerman
    Luke Timmerman@ldtimmerman
    RT @daphnezohar: Some argue that healthcare VC has outperformed other sectors: bit.ly/ordh2Z #bioVC
    Tue, Nov 22 2011 09:17:28
  22. daphnezohar
    Daphne Zohar@daphnezohar
    @_rjw It's a combination of VCs closing shop & moving later stage #biovc
    Tue, Nov 22 2011 09:18:44
  23. ldtimmerman
    Luke Timmerman@ldtimmerman
    What will it take for biotech to rekindle enthusiasm among VCs and public investors? A couple more Pharmassets? @xconomy #bioVC
    Tue, Nov 22 2011 09:19:00
  24. Michael_Gilman
    Michael Gilman@Michael_Gilman
    #bioVC Isn't it really a crisis of conviction? Many VCs no longer believe biotech investing works, therefore can't convince LPs...
    Tue, Nov 22 2011 09:19:22
  25. AkikoaCom
    Jens Eckstein@AkikoaCom
    add the fact that we are one of the most regulated industries with the ultimate judgement (FDA) coming when most VC money is all in #biovc
    Tue, Nov 22 2011 09:20:07

Did you find this story interesting? Be the first to or comment.

Liked!

Lilly O'Flaherty

Marketing Coordinator for Xconomy.com. PR maven in-progress. Cheese enthusiast.

2stories
2followers
1following
Total views
703

Sorry.

This URL is already in use. Please choose another URL.
Edit URL

Storify

@Storify

Are you sure?

Are you sure you want to delete this story?

Are you sure?

Are you sure you want to flag this story?